在急性不补偿性心力衰竭中使用胆固醇:COLICA试验
Domingo Pascual-Figal1,2,3, Julio Núñez3,4, Maria T Pérez-Martínez1
1Cardiology Department, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB Pascual Parrilla, Universidad de Murcia, Ctra. Madrid-Cartagena s/n, 30120 Murcia, Spain.
European heart journal
|August 30, 2024
概括
胆固醇有效地减少了急性心力衰竭 (AHF) 患者的炎症. 虽然它没有改善NT-proBNP水平或预防心力衰竭事件,但它降低了对静脉注射furosemide的需求.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 急性心力衰竭 (AHF) 与增强的炎症反应有关,影响患者的结果.
- 科尔奇辛因其在心血管疾病中的抗炎性质而闻名,此前尚未在AHF中进行研究.
研究的目的:
- 评估在患有急性心力衰竭的患者中胆固醇的疗效和安全性.
- 评估菌素对炎症标志物和AHF的临床结果的影响.
主要方法:
- 一个多中心,随机,双盲,安慰剂对照试验,涉及278名AHF患者.
- 患者在呈现后24小时内接受了胆固醇 (加载剂量2mg,然后每12小时0.5mg,持续8周) 或安慰剂.
- 主要终点是8周后N-终端B型亲尿素 (NT-proBNP) 水平的时间平均降低.
主要成果:
- 在胆固醇和安慰剂组之间,NT-proBNP减少没有显著差异.
- 科尔奇辛证明了C-反应蛋白和IN-6水平的显著降低.
- 心力衰竭发作恶化的情况没有差异,但使用素与静脉注射罗西米德的需求减少有关.
- 腹在用黄素时更频繁,但药物戒断率相似.
结论:
- 胆固醇是安全的,并减少AHF患者的炎症.
- 胆固醇在减少NT-proBNP或预防心力衰竭事件方面没有与安慰剂相比较的效果.
- 科尔奇辛可能有助于降低AHF的利尿剂需求.
相关概念视频
Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
Renal Failure: Dose Adjustments
69
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
69
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Anticholinesterase Agents: Poisoning and Treatment
813
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
813
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322


